Hepatitis C: Medicines Technology and Market Landscape (2015)

This landscape analysis surveys the current state of technologies for the treatment of hepatitis C virus (HCV), as well as market dynamics that affect the affordability and accessibility of HCV therapeutics. HCV treatment falls within the ambit of UNITAID’s mission because it is a major HIV coinfection and a leading cause of morbidity and mortality among people living with HIV. Strategic Objective 3 of the UNITAID Strategy 2013−2016 specifically refers to viral hepatitis, notably hepatitis B and C.